- Clinical Trials
- April 2024
- 60 Pages
Global
From €1427EUR$1,500USD£1,222GBP
- Report
- March 2024
- 196 Pages
Global
From €3210EUR$3,374USD£2,749GBP
€3567EUR$3,749USD£3,054GBP
- Report
- May 2024
- 129 Pages
From €6184EUR$6,499USD£5,295GBP
- Report
- January 2022
- 60 Pages
Global
From €3758EUR$3,950USD£3,218GBP
- Report
- January 2022
- 200 Pages
Global
From €7136EUR$7,500USD£6,110GBP
- Clinical Trials
- February 2022
- 96 Pages
Global
From €2379EUR$2,500USD£2,037GBP
- Clinical Trials
- June 2020
- 79 Pages
Global
From €2379EUR$2,500USD£2,037GBP
- Drug Pipelines
- August 2020
- 76 Pages
Global
From €1903EUR$2,000USD£1,629GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,941USD£3,102GBP
- Drug Pipelines
- June 2021
- 80 Pages
Global
From €1903EUR$2,000USD£1,629GBP
Trigeminal Neuralgia (TN) is a chronic pain disorder that affects the trigeminal nerve, one of the largest nerves in the head. It is characterized by episodes of intense, stabbing pain in the face, usually on one side. Treatment for TN typically involves medications, such as anticonvulsants, antidepressants, and muscle relaxants. These drugs are part of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological and psychiatric disorders.
The CNS drug market is highly competitive, with many large pharmaceutical companies developing and marketing drugs for the treatment of neurological and psychiatric disorders. Companies such as Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis are some of the major players in the CNS drug market. Other companies, such as Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals, also have a presence in the market. Show Less Read more